{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:48:09Z","timestamp":1793119689733,"version":"4.5.0"},"reference-count":122,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>\n                    Ovarian hyperstimulation syndrome (OHSS) is a serious iatrogenic complication of ovarian stimulation during\n                    <jats:italic>in vitro<\/jats:italic>\n                    fertilisation (IVF) treatment and is associated with significant morbidity and a small risk of mortality. Women with polycystic ovary syndrome (PCOS) are at a substantially increased risk of developing OHSS compared to those without. This paper reviews the current evidence for strategies to mitigate the risk of OHSS in this patient population. In order to minimise the risk of OHSS, clinicians should identify patients at high risk prior to commencing treatment and provide adequate pre-treatment counselling regarding the risks and benefits of IVF treatment, as well as alternative treatment options. Strategies that can reduce the risk of OHSS include co-treatment with metformin in gonadotropin releasing hormone (GnRH) agonist cycles, use of GnRH antagonist or PPOS protocols, appropriate gonadotropin dosing, the use of a GnRH agonist trigger for oocyte maturation in antagonist or PPOS protocols, cryopreservation of all embryos with deferred frozen embryo transfer, and treatment with dopamine-agonists after oocyte collection.\n                    <jats:italic>In vitro<\/jats:italic>\n                    maturation (IVM) offers an alternative with no risk of OHSS, however currently has a lower cumulative live birth rate than conventional IVF. These strategies can prevent significant early and late OHSS in women with PCOS and should be used to optimise the safety of IVF for this high-risk population, striving for OHSS-free treatment for all patients undergoing IVF.\n                  <\/jats:p>","DOI":"10.3389\/fendo.2025.1507857","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T01:19:54Z","timestamp":1741828794000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":27,"title":["Minimising OHSS in women with PCOS"],"prefix":"10.3389","volume":"16","author":[{"given":"Sebastian","family":"Leathersich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Roche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"key":"B1","first-page":"1293","volume-title":"Speroff's Clinical Gynecologic Endocrinology and Infertility","author":"Taylor","year":"2020"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/ajo.12389","article-title":"RANZCOG CREI consensus statement on treatment of ovarian hyperstimulation syndrome","volume":"55","author":"Kwik","year":"2015","journal-title":"Aust New Z J Obstetrics Gynaecology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2023.11.013","article-title":"Prevention of moderate and severe ovarian hyperstimulation syndrome: a guideline","volume":"121","year":"2024","journal-title":"Fertility Sterility"},{"key":"B4","article-title":"Pathogenesis, clinical manifestations, and diagnosis of ovarian hyperstimulation syndrome","volume-title":"UpToDate","author":"Busso","year":"2024"},{"key":"B5","article-title":"Prevention of ovarian hyperstimulation syndrome","volume-title":"UpToDate","author":"Busso","year":"2024"},{"key":"B6","volume-title":"The management of Ovarian Hyperstimulation Syndrome: Green-Top Guideline No. 5","year":"2016"},{"key":"B7","volume-title":"Ovarian Hyperstimulation Syndrome","year":"2018"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2006.05.049","article-title":"Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates","volume":"86","author":"Acevedo","year":"2006","journal-title":"Fertility Sterility"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0412.2012.01399.x","article-title":"The gonadotropin-releasing hormone antagonist protocol \u2013 the protocol of choice for the polycystic ovary syndrome patient undergoing controlled ovarian stimulation","volume":"91","author":"Kol","year":"2012","journal-title":"Acta Obstet Gynecol Scand"},{"key":"B10","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.fertnstert.2007.02.002","article-title":"The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study","volume":"89","author":"Engmann","year":"2008","journal-title":"Fertility Sterility"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2020.06.004","article-title":"Trends in ovarian hyperstimulation syndrome hospitalization rates in the USA: an ongoing concern","volume":"41","author":"Rotshenker-Olshinka","year":"2020","journal-title":"Reprod BioMedicine Online"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2022.08.014","article-title":"Emergency department utilization for ovarian hyperstimulation syndrome","volume":"60","author":"Schon","year":"2022","journal-title":"Am J Emergency Med"},{"key":"B13","volume-title":"State of the fertility sector 2021\/22","year":"2022"},{"key":"B14","volume-title":"Assisted reproductive technology in Australia and New Zealand 2019","author":"Newman","year":"2021"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2020.04.004","article-title":"Ovarian hyperstimulation syndrome after assisted reproductive technologies: trends, predictors, and pregnancy outcomes","volume":"114","author":"Schirmer","year":"2020","journal-title":"Fertility Sterility"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2008.09.054","article-title":"Cost analysis model of outpatient management of ovarian hyperstimulation syndrome with paracentesis: \"tap early and often\" versus hospitalization","volume":"93","author":"Csokmay","year":"2010","journal-title":"Fertility Sterility"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/aogs.12128","article-title":"Conservative medical treatment of ovarian hyperstimulation syndrome: a single center series and cost analysis study","volume":"92","author":"Casals","year":"2013","journal-title":"Acta Obstetricia Gynecologica Scandinavica"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2018.1551226","article-title":"A cost-effectiveness analysis comparing the originator follitropin alfa to its biosimilars in patients undergoing a medically assisted reproduction program from a French perspective","volume":"21","author":"Grynberg","year":"2019","journal-title":"J Med Economics"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/jocn.16701","article-title":"Managing ovarian hyperstimulation syndrome: a qualitative interview study with women and healthcare professionals","volume":"32","author":"Lumley","year":"2023","journal-title":"J Clin Nurs"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2702.2006.01801.x","article-title":"Infertile couples\u2019 experience of family stress while women are hospitalized for ovarian hyperstimulation syndrome during infertility treatment","volume":"17","author":"Chang","year":"2008","journal-title":"J Clin Nurs"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/j.0001-6349.2005.00788.x","article-title":"Polycystic ovaries and ovarian hyperstimulation syndrome: a systematic review","volume":"84","author":"Tummon","year":"2005","journal-title":"Acta Obstetricia Gynecologica Scandinavica"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dew051","article-title":"Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF\/ICSI cycles","volume":"31","author":"Toftager","year":"2016","journal-title":"Hum Reprod"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dem254","article-title":"Serum anti-mullerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles","volume":"23","author":"Lee","year":"2008","journal-title":"Hum Reprod"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1186\/s12978-015-0053-4","article-title":"Optimal cutoff value of basal anti-Mullerian hormone in Iranian infertile women for prediction of ovarian hyper-stimulation syndrome and poor response to stimulation","volume":"12","author":"Aghssa","year":"2015","journal-title":"Reprod Health"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2005.10.052","article-title":"Elevated serum mullerian-inhibiting substance may be a marker for ovarian hyperstimulation syndrome in normal women undergoing in vitro fertilization","volume":"85","author":"Nakhuda","year":"2006","journal-title":"Fertility Sterility"},{"key":"B26","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ajog.2014.02.026","article-title":"Characterization of women with elevated antiMullerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes","volume":"211","author":"Tal","year":"2014","journal-title":"Am J Obstetrics Gynecology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/14767058.2016.1272567","article-title":"Can AMH levels predict the need for increased medication during IVF\/ICSI in PCOS women","volume":"31","author":"Kamel","year":"2018","journal-title":"J Maternal-Fetal Neonatal Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s10815-011-9627-4","article-title":"Serum anti-Mullerian hormone and antral follicle count as predictive markers of OHSS in ART cycles","volume":"28","author":"Ocal","year":"2011","journal-title":"J Assisted Reprod Genet"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-015-3723-0","article-title":"Predictive factors of early moderate\/severe ovarian hyperstimulation syndrome in non-polycystic ovarian syndrome patients: a statistical model","volume":"292","author":"Ashrafi","year":"2015","journal-title":"Arch Gynecology Obstetrics"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2012.05.042","article-title":"Prediction of in vitro fertilization outcome at different antral follicle count thresholds in a prospective cohort of 1,012 women","volume":"98","author":"Kannamannadiar","year":"2012","journal-title":"Fertility Sterility"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/ajo.12515","article-title":"Ovarian hyperstimulation syndrome: a case control study investigating risk factors","volume":"56","author":"Shields","year":"2016","journal-title":"Aust New Z J Obstetrics Gynaecology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2009.05.092","article-title":"Factors associated with ovarian hyperstimulation syndrome (OHSS) and its effect on assisted reproductive technology (ART) treatment and outcome","volume":"94","author":"Luke","year":"2010","journal-title":"Fertility Sterility"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.11995","article-title":"Association of metformin with pregnancy outcomes in women with polycystic ovarian syndrome undergoing in vitro fertilization; a systematic review and meta-analysis","volume":"3","author":"Wu","year":"2020","journal-title":"JAMA Network Open"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1210\/en.2014-1765","article-title":"Metformin regulates ovarian angiogenesis and follicular development in a female polycystic ovary syndrome rat model","volume":"156","author":"Di Pietro","year":"2015","journal-title":"Endocrinology"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1186\/1757-2215-6-62","article-title":"Metformin decreases the incidence of ovarian hyperstimulation syndrome: an experimental study","volume":"6","author":"Elia","year":"2013","journal-title":"J Ovarian Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2011.09.020","article-title":"Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial","volume":"96","author":"Palomba","year":"2011","journal-title":"Fertility Sterility"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006105.pub4","article-title":"Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome","author":"Tso","year":"2020","journal-title":"Cochrane Database Systematic Rev"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1080\/14767050600761893","article-title":"Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer","volume":"22","author":"Doldi","year":"2006","journal-title":"Gynecological Endocrinol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dew268","article-title":"A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial","volume":"31","author":"Jacob","year":"2016","journal-title":"Hum Reprod"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1080\/09513590.2021.1981282","article-title":"Myoinositol versus metformin pretreatment in GnRH-antagonist cycle for women with PCOS undergoing IVF: a double-blinded randomized controlled study","volume":"38","author":"Rajasekaran","year":"2022","journal-title":"Gynecological Endocrinol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1080\/09513590.2019.1576620","article-title":"Comparison of the effect of two combinations of myo-inositol and D-chiro-inositol in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial","volume":"35","author":"Mendoza","year":"2019","journal-title":"Gynecological Endocrinol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001750.pub4","article-title":"Gonadotrophin-releasing hormone antagonists for assisted reproductive technology","author":"Al-Inany","year":"2016","journal-title":"Cochrane Database Systematic Rev"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006919.pub4","article-title":"Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction","author":"Siristatidis","year":"2015","journal-title":"Cochrane Database Systematic Rev"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-022-08400-z","article-title":"Conventional GnRH antagonist protocols versus long GnRH agonist protocol in IVF\/ICSI cycles of polycystic ovary syndrome women: a systematic review and meta-analysis","volume":"12","author":"Kadoura","year":"2022","journal-title":"Sci Rep"},{"key":"B45","volume-title":"International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome Melbourne","author":"Teede","year":"2023"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/hropen\/hoaa009","article-title":"ESHRE guideline: ovarian stimulation for IVF\/ICSI","volume":"2020","author":"Bosch","year":"2020","journal-title":"Hum Reprod Open"},{"key":"B47","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.fertnstert.2015.03.022","article-title":"Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization","volume":"104","author":"Kuang","year":"2015","journal-title":"Fertility Sterility"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013827.pub2","article-title":"Progestogens for prevention of luteinising hormone (LH) surge in women undergoing controlled ovarian hyperstimulation as part of an assisted reproductive technology (ART) cycle","author":"Glujovsky","year":"2023","journal-title":"Cochrane Database Systematic Rev"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1224858","article-title":"Efficacy of progestin-primed ovarian stimulation in women with polycystic ovary syndrome undergoing in vitro fertilization: a systematic review and meta-analysis","volume":"14","author":"Yang","year":"2023","journal-title":"Front Endocrinol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-023-07269-1","article-title":"GnRH antagonist protocol versus progestin-primed ovarian stimulation in patients with polycystic ovary syndrome: a systematic review and meta-analysis","volume":"309","author":"Deng","year":"2024","journal-title":"Arch Gynecology Obstetrics"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2024.01.027","article-title":"A randomized controlled trial to compare the live birth rate of the first frozen embryo transfer following the progestin-primed ovarian stimulation protocol vs. the antagonist protocol in women with an anticipated high ovarian response","volume":"121","author":"Chen","year":"2024","journal-title":"Fertility Sterility"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deae047","article-title":"Ovarian response and embryo ploidy following oral micronized progesterone-primed ovarian stimulation versus GnRH antagonist protocol. A prospective study with repeated ovarian stimulation cycles","volume":"39","author":"Vidal","year":"2024","journal-title":"Hum Reprod"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmw047","article-title":"New stimulation regimens: endogenous and exogenous progesterone use to block the LH surge during ovarian stimulation for IVF","volume":"23","author":"Massin","year":"2017","journal-title":"Hum Reprod Update"},{"key":"B54","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10815-019-01662-z","article-title":"Success rates in minimal stimulation cycle IVF with clomiphene citrate only","volume":"37","author":"Abe","year":"2020","journal-title":"J Assisted Reprod Genet"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmaa035","article-title":"Mild versus conventional ovarian stimulation for IVF in poor, normal and hyper-responders: a systematic review and meta-analysis","volume":"27","author":"Datta","year":"2021","journal-title":"Hum Reprod Update"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-100206","article-title":"Avoiding OHSS: controlled ovarian low-dose stimulation in women with PCOS","volume":"76","author":"Fischer","year":"2016","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1186\/s12905-023-02473-2","article-title":"Introduce an optimal method of ovarian stimulation in the polycystic ovarian syndrome affected: a randomized controlled trial","volume":"23","author":"Yahyaei","year":"2023","journal-title":"BMC Women's Health"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpobgyn.2022.102307","article-title":"Association between the number of oocytes and cumulative live birth rate: a systematic review","volume":"87","author":"Neves","year":"2023","journal-title":"Best Pract Res Clin Obstetrics Gynaecology"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2016.10.033","article-title":"Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial","volume":"107","author":"Nyboe Andersen","year":"2017","journal-title":"Fertility Sterility"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2018.12.032","article-title":"Individualization of the starting dose of follitropin delta reduces the overall OHSS risk and\/or the need for additional preventive interventions: cumulative data over three stimulation cycles","volume":"38","author":"Fern\u00e1ndez-S\u00e1nchez","year":"2019","journal-title":"Reprod BioMedicine Online"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dex319","article-title":"Individualized versus standard FSH dosing in women starting IVF\/ICSI: an RCT. Part 2: The predicted hyper responder","volume":"32","author":"Oudshoorn","year":"2017","journal-title":"Hum Reprod"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012693.pub2","article-title":"Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF\/ICSI)","volume":"2","author":"Lensen","year":"2018","journal-title":"Cochrane Database Systematic Rev"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1186\/s12958-023-01173-8","article-title":"Can AMH levels predict the need to step up FSH dose for controlled ovarian stimulation following a long GnRH agonist protocol in PCOS women","volume":"21","author":"Huang","year":"2023","journal-title":"Reprod Biol Endocrinol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012693.pub3","article-title":"Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF\/ICSI)","author":"Ngwenya","year":"2024","journal-title":"Cochrane Database Systematic Rev"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2022.07.010","article-title":"An interpretable machine learning model for individualized gonadotrophin starting dose selection during ovarian stimulation","volume":"45","author":"Hariton","year":"2022","journal-title":"Reprod BioMedicine Online"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1186\/s12958-021-00744-x","article-title":"Dose adjustment of follicle-stimulating hormone (FSH) during ovarian stimulation as part of medically-assisted reproduction in clinical studies: a systematic review covering 10 years (2007\u20132017)","volume":"19","author":"Fatemi","year":"2021","journal-title":"Reprod Biol Endocrinol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002811.pub4","article-title":"Coasting (withholding gonadotrophins) to prevent ovarian hyperstimulation syndrome","author":"D'Angelo","year":"2017","journal-title":"Cochrane Database Systematic Rev"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1080\/14647270600787575","article-title":"The optimal length of 'coasting protocol' in women at risk of ovarian hyperstimulation syndrome undergoing in vitro fertilization","volume":"9","author":"Nardo","year":"2006","journal-title":"Hum Fertility"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241814185","article-title":"Beyond the umbrella: a systematic review of the interventions for the prevention of and reduction in the incidence and severity of ovarian hyperstimulation syndrome in patients who undergo in vitro fertilization treatments","volume":"24","author":"Palomba","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deae102","article-title":"Protocol change improves live birth and recurrent cycle cancellation rates after a previous IVF cycle cancellation: an analysis of 13 000 autologous cycles reported to SART CORS","volume":"39","author":"Kahn","year":"2024","journal-title":"Hum Reprod"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.2.8197","article-title":"Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization","volume":"87","author":"Fauser","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008046.pub4","article-title":"Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology","author":"Youssef","year":"2014","journal-title":"Cochrane Database Systematic Rev"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dep246","article-title":"GnRHa to trigger final oocyte maturation: a time to reconsider","volume":"24","author":"Humaidan","year":"2009","journal-title":"Hum Reprod"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2018.02.003","article-title":"Luteal phase support after gonadotropin-releasing hormone agonist triggering: does it still matter","volume":"109","author":"Benadiva","year":"2018","journal-title":"Fertility Sterility"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-023-07285-1","article-title":"Effect of GnRH agonist trigger with or without low-dose hCG on reproductive outcomes for PCOS women with freeze-all strategy: a propensity score matching study","volume":"309","author":"Wang","year":"2024","journal-title":"Arch Gynecology Obstetrics"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/der463","article-title":"Reproductive outcome of fresh or frozen-thawed embryo transfer is similar in high-risk patients for ovarian hyperstimulation syndrome using GnRH agonist for final oocyte maturation and intensive luteal support","volume":"27","author":"Imbar","year":"2012","journal-title":"Hum Reprod"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2011.03.109","article-title":"Comparison of \"triggers\" using leuprolide acetate alone or in combination with low-dose human chorionic gonadotropin","volume":"95","author":"Shapiro","year":"2011","journal-title":"Fertility Sterility"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/s1472-6483(10)60006-5","article-title":"Luteal phase rescue in high-risk OHSS patients by GnRHa triggering in combination with low-dose HCG: a pilot study","volume":"18","author":"Humaidan","year":"2009","journal-title":"Reprod BioMedicine Online"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/s1472-6483(10)60612-8","article-title":"Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF\/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study","volume":"13","author":"Humaidan","year":"2006","journal-title":"Reprod BioMedicine Online"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2008.12.042","article-title":"1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study","volume":"93","author":"Humaidan","year":"2010","journal-title":"Fertility Sterility"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1186\/1757-2215-7-35","article-title":"HCG (1500IU) administration on day 3 after oocytes retrieval, following GnRH-agonist trigger for final follicular maturation, results in high sufficient mid luteal progesterone levels - a proof of concept","volume":"7","author":"Haas","year":"2014","journal-title":"J Ovarian Res"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1080\/09513590.2017.1379496","article-title":"Day two post retrieval 1500 IUI hCG bolus, progesterone-free luteal support post GnRH agonist trigger - a proof of concept study","volume":"34","author":"Vanetik","year":"2018","journal-title":"Gynecological Endocrinol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/det124","article-title":"Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG","volume":"28","author":"Seyhan","year":"2013","journal-title":"Hum Reprod"},{"key":"B84","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.fertnstert.2016.07.176","article-title":"Prospective double-blind randomized placebo controlled clinical trial comparing pregnancy rates after co-administration of low dose HCG at the time of GnRH-agonist trigger or 35 hours later, for the prevention of OHSS","volume":"106","author":"Maslow","year":"2016","journal-title":"Fertility Sterility"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2020.11.008","article-title":"How frequent is severe ovarian hyperstimulation syndrome after GnRH agonist triggering in high-risk women? A systematic review and meta-analysis","volume":"42","author":"Ioannidou","year":"2021","journal-title":"Reprod BioMedicine Online"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2011.12.046","article-title":"Etiology of OHSS and use of dopamine agonists","volume":"97","author":"Soares","year":"2012","journal-title":"Fertility Sterility"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008605.pub4","article-title":"Dopamine agonists for preventing ovarian hyperstimulation syndrome","author":"Tang","year":"2021","journal-title":"Cochrane Database Systematic Rev"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-62-6-1250","article-title":"The dependency of folliculogenesis and corpus luteum function on pulsatile gonadotropin secretion in cycling women using a gonadotropin-releasing hormone antagonist as a probe","volume":"62","author":"Mais","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/16.4.608","article-title":"Embryo implantation and GnRH antagonists: ovarian actions of GnRH antagonists","volume":"16","author":"Ortmann","year":"2001","journal-title":"Hum Reprod"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1210\/endo.135.5.7956897","article-title":"Expression and regulation of gonadotropin-releasing hormone (GnRH) and GnRH receptor messenger ribonucleic acids in human granulosa-luteal cells","volume":"135","author":"Peng","year":"1994","journal-title":"Endocrinology"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.12572","article-title":"Serum vascular endothelial growth factor levels following luteal gonadotrophin-releasing hormone antagonist administration in women with severe early ovarian hyperstimulation syndrome","volume":"121","author":"Lainas","year":"2014","journal-title":"BJOG: Int J Obstetrics Gynaecology"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2006.01.046","article-title":"Gonadotropin-releasing hormone antagonists do not influence the secretion of steroid hormones but affect the secretion of vascular endothelial growth factor from human granulosa luteinized cell cultures","volume":"86","author":"Asimakopoulos","year":"2006","journal-title":"Fertility Sterility"},{"key":"B93","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12905-017-0466-z","article-title":"Sequential E2 levels not ovarian maximal diameter estimates were correlated with outcome of cetrotide therapy for management of women at high-risk of ovarian hyperstimulation syndrome: a randomized controlled study","volume":"17","author":"Salama","year":"2017","journal-title":"BMC Womens Health"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-015-0190-y","article-title":"Can steroidal ovarian suppression during the luteal phase after oocyte retrieval reduce the risk of severe OHSS","volume":"8","author":"Wang","year":"2015","journal-title":"J Ovarian Res"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-019-05163-3","article-title":"The effect of luteal GnRH antagonist on moderate and severe early ovarian hyperstimulation syndrome during in vitro fertilization treatment: a prospective cohort study","volume":"300","author":"Zeng","year":"2019","journal-title":"Arch Gynecology Obstetrics"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1513873","article-title":"Fresh versus frozen embryos for infertility in the polycystic ovary syndrome","volume":"375","author":"Chen","year":"2016","journal-title":"New Engl J Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2011.05.050","article-title":"Evidence of impaired endometrial receptivity after ovarian stimulation for in vitro fertilization: a prospective randomized trial comparing fresh and frozen-thawed embryo transfer in normal responders","volume":"96","author":"Shapiro","year":"2011","journal-title":"Fertility Sterility"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmad011","article-title":"Obstetric and neonatal outcomes after natural versus artificial cycle frozen embryo transfer and the role of luteal phase support: a systematic review and meta-analysis","volume":"29","author":"Zaat","year":"2023","journal-title":"Hum Reprod Update"},{"key":"B99","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1093\/humrep\/dey388","article-title":"Higher probability of live-birth in high, but not normal, responders after first frozen-embryo transfer in a freeze-only cycle strategy compared to fresh-embryo transfer: a meta-analysis","volume":"34","author":"Bosdou","year":"2019","journal-title":"Hum Reprod"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2019.04.014","article-title":"Use of cabergoline and post-collection GnRH antagonist administration for prevention of ovarian hyperstimulation syndrome","volume":"39","author":"Shrem","year":"2019","journal-title":"Reprod BioMedicine Online"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dex262","article-title":"An improved IVM method for cumulus-oocyte complexes from small follicles in polycystic ovary syndrome patients enhances oocyte competence and embryo yield","volume":"32","author":"S\u00e1nchez","year":"2017","journal-title":"Hum Reprod"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1007\/s10815-019-01551-5","article-title":"Biphasic in vitro maturation (CAPA-IVM) specifically improves the developmental capacity of oocytes from small antral follicles","volume":"36","author":"Sanchez","year":"2019","journal-title":"J Assisted Reprod Genet"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1007\/s10815-019-01677-6","article-title":"Live births after oocyte in vitro maturation with a prematuration step in women with polycystic ovary syndrome","volume":"37","author":"Vuong","year":"2020","journal-title":"J Assisted Reprod Genet"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deae108.980","article-title":"P-650 Cumulative live birth rate after use of capacitation in vitro maturation in women with predicted excessive response to ovarian stimulation: an analysis of 1,563 cycles","volume":"39","author":"Ho","year":"2024","journal-title":"Hum Reprod"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deae108.223","article-title":"O-190 Hormone-free versus FSH-primed infertility treatment of women with polycystic ovary syndrome using biphasic in vitro maturation: a randomised clinical trial","volume":"39","author":"Vuong","year":"2024","journal-title":"Hum Reprod"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deab243","article-title":"In vitro maturation without gonadotropins versus in vitro fertilization with hyperstimulation in women with polycystic ovary syndrome: a non-inferiority randomized controlled trial","volume":"37","author":"Zheng","year":"2022","journal-title":"Hum Reprod"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deaa240","article-title":"In-vitro maturation of oocytes versus conventional IVF in women with infertility and a high antral follicle count: a randomized non-inferiority controlled trial","volume":"35","author":"Vuong","year":"2020","journal-title":"Hum Reprod"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1007\/s10815-023-02752-9","article-title":"Cumulative live birth rate after oocyte in vitro maturation with a pre-maturation step in women with polycystic ovary syndrome or high antral follicle count","volume":"40","author":"Pham","year":"2023","journal-title":"J Assisted Reprod Genet"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dead273","article-title":"Clinical outcomes from ART in predicted hyperresponders: in vitro maturation of oocytes versus conventional ovarian stimulation for IVF\/ICSI","volume":"39","author":"Mostinckx","year":"2024","journal-title":"Hum Reprod"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deaa190","article-title":"Outcome of in-vitro oocyte maturation in patients with PCOS: does phenotype have an impact","volume":"35","author":"Mackens","year":"2020","journal-title":"Hum Reprod"},{"key":"B111","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1093\/humrep\/deu248","article-title":"In vitro maturation as an alternative to standard in vitro fertilization for patients diagnosed with polycystic ovaries: a comparative analysis of fresh, frozen and cumulative cycle outcomes","volume":"30","author":"Walls","year":"2015","journal-title":"Hum Reprod"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1007\/s10815-021-02180-7","article-title":"Fresh embryo transfer versus freeze-only after in vitro maturation with a pre-maturation step in women with high antral follicle count: a randomized controlled pilot study","volume":"38","author":"Vuong","year":"2021","journal-title":"J Assisted Reprod Genet"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1093\/hropen\/hoz034","article-title":"The perspective of women with an increased risk of OHSS regarding the safety and burden of IVF: a discrete choice experiment","volume":"2020","author":"Braam","year":"2020","journal-title":"Hum Reprod Open"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-69165-1","article-title":"Optimizing oocyte yield utilizing a machine learning model for dose and trigger decisions, a multi-center, prospective study","volume":"14","author":"Canon","year":"2024","journal-title":"Sci Rep"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22073785","article-title":"In vitro activation early follicles: from the basic science to the clinical perspectives","volume":"22","author":"Vo","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2022.04.027","article-title":"Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study","volume":"118","author":"Elkind-Hirsch","year":"2022","journal-title":"Fertility Sterility"},{"key":"B117","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12902-023-01500-5","article-title":"Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review","volume":"23","author":"Zhou","year":"2023","journal-title":"BMC Endocrine Disord"},{"key":"B118","article-title":"Ozempic\u00ae (semaglutide) injection: highlights of prescribing information","year":"2017"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.jogoh.2024.102850","article-title":"The effect of intravenous calcium gluconate on the prevention of ovarian hyperstimulation syndrome. (A randomized clinical trial)","volume":"53","author":"Lotfalizadeh","year":"2024","journal-title":"J Gynecology Obstetrics Hum Reprod"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.17491","article-title":"Kallistatin prevents ovarian hyperstimulation syndrome by regulating vascular leakage","volume":"26","author":"Huang","year":"2022","journal-title":"J Cell Mol Med"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.22038\/IJBMS.2022.64010.14096","article-title":"Coenzyme Q10 improves ovarian histology and attenuates the expression of angiogenesis-associated proteins in the ovary of rats with experimental hyperstimulation syndrome","volume":"25","author":"Darabi","year":"2022","journal-title":"Iranian J Basic Med Sci"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1155\/ije\/1634072","article-title":"Efficacy of local N-acetylcysteine administration in mitigating OHSS parameters: A comparative analysis with dopaminergic agonist in the OHSS model","volume":"2024","author":"Letras-Luna","year":"2024","journal-title":"Int J Endocrinol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1507857\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T01:20:02Z","timestamp":1741828802000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1507857\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":122,"alternative-id":["10.3389\/fendo.2025.1507857"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1507857","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,13]]},"article-number":"1507857"}}